The purpose of this study is to evaluate and compare the survival outcome of patients with first recurrence of GBM undergoing surgical debulking/resection followed by either implantation of the SC9 device and repeat BBB opening in association with carboplatin chemotherapy or standard of care second line chemotherapy with either lomustine or temozolomide (per best physician's choice and best practice).

This is an exploratory study in cancer biomarker research, hoping to identify cell-signaling using DNA, in patients with SCLC.

The purpose of this study is to evaluate a new test being developed by Tempus for patients with Non-Small Cell Lung Cancer (NSCLC). The goal of this new test is to predict the likelihood of a patient's cancer coming back after treatment, and to further explore changes in patient's tumors throughout treatment to see how they respond.

The purpose of this study is to determine if it is possible to identify biomarkers that tell us what type of response a person with metastatic breast cancer (MBC) will have to "antibody-drug conjugates" (ADCs).

The purpose of this research study is to create a Lymphoma Registry of patients who are willing to complete the study's comprehensive assessment. The assessment is designed to gather information on memory, nutritional status, mental health, and level social support. It is also designed to understand how well you carry out your day to day activities and to briefly describe what other medical conditions you may have. This assessment will help your health care team determine your "functional age" (the age you function at) as compared to how many years old you are. We will also ask you to complete questionnaires that ask questions about your personal health history, such as exercise and smoking,

To initiate and evaluate a multilevel navigation intervention to promote lung cancer screening among Black/African Americans

This study is being done to answer the following question: Can we lower the chance of your bladder cancer growing or spreading by using one type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel, instead of the usual BCG therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your bladder cancer. The usual approach is defined as care most people get for bladder cancer.

Some female cancers may be genetic, meaning they are passed down from a parent through DNA (our genetic code or roadmap). In people with certain types of ovarian and uterine cancer, it may be helpful to test their DNA for any errors that can cause cancer. There are lots of important pieces of information to share when someone is diagnosed with cancer, and we are exploring a new way to share information. Patients with certain types of ovarian or uterine cancers will watch a short video that explains what genetic testing is and why it is so important. They will fill out a survey about what they think about the video and if the information is helpful.

We are implementing a digital health intervention, mPATH-Cloud, in one community health center. Patients who receive a link to the mPATH-Cloud website will be able to view a video designed to help them choose the colorectal cancer (CRC) screening test that is best for them. Patients who select colonoscopy will receive a referral from their primary care provider. Patients who do not select colonoscopy will receive a FIT in the mail. We will assess the feasibility and effectiveness of implementing mPATH-Cloud in combination with mailed FIT outreach for increasing CRC screening among community health center patients.

No guidelines or interventions for patients and their family caregivers exist to support patient adherence to a new medication (venetoclax) and their quality of life. Our research team seeks to understand the real experience and care needs of patients and their family caregivers with the new AML treatment. With the information we learn from this study, we will be able to develop an effective support program for patients with AML and their family caregivers to manage their symptoms at home and improve their quality of life.